Clinical Studies On Tangguankang In Treating Coronary Heart Disease Complicated By Type 2 Dlabetes Mellitus And In The Influence On The Levels Of SICAM-1,sVCAM-1,IGF-1 And VEGF In Plasma

To observe the clinical effects of TangGuanKang in treating CHD complicated by DM (type 2) and the latent pharmacological mechanism of its therapeutic effects, We have established systemic clinical studies.The results show that: (1) the total therapeutic effective rate of TangGuanKang is 91.18%,significantly better than that of the control group (P<0.05); (2)TangGuanKang can significantly improve the patients' clinical symptoms and experimental data, including FBG, P2hBG, HbA1c,blood lipid , blood viscosity, left ventricular function, TIB, angina pectoris, insulin resistance and the function of islet B cells of the Pancreas; (3)TangGuanKang can significantly improve the level of sICAM-l,sVCAM-l,IGF-l and VEGF in plasma; ï¹–he mechanism of TangGuanKang in treating this disease may be through the modern pharmacological functions of its ingredients; through descending the level of sICAM-1 and sVCAM-1 in plasma which can get AS formation and the inflammation of vascular endothelium inhibited and prevent the clots of AS from rupturing; and through promoting the expression of IGF-1 and VEGF to lower blood glucose, regulate blood lipid, improve IR and left ventricular function, promote collateral circulation in ischemic cardiac muscles, avoid AMI and improve the prognosis of this disease.